STAT5B has been implicated in migration [56], whereas loss of STAT5A was associated with disease progression [54], highlighting the importance in future studies to distinguish between the two STAT5 proteins to enrich clinical efficacy of STAT5 as a biomarker for breast cancer. The gene discussed is STAT5B; the disease is breast carcinoma.